Massachusetts General Hospital: Hematologic Neoplasms trials
The registry lists 15 Hematologic Neoplasms studies with Massachusetts General Hospital as lead sponsor. 6 are open to participants now and 1 have results posted.
Early Phase 1 1Phase 2 2No phase 12(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Symptom Monitoring and Management Intervention After CAR-TNot yet recruitingNCT07886190Not applicable
- Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney TransplantationRecruitingNCT07358195Early Phase 1
- Multidisciplinary Intervention for Adults With Chronic Graft-versus-host DiseaseRecruitingNCT06910969Not applicable
- Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell TransplantationRecruitingNCT06676852Not applicable
- BMT-CARE: Psychosocial Intervention for Transplant CaregiversRecruitingNCT06472089Not applicable
- Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular TherapyRecruitingNCT05646576Not applicable
- Radiation Post-CAR T in Refractory LymphomaTerminatedNCT04473937Not applicableResults posted
- Intervention for Fatigue in HCT RecipientsCompletedNCT05715047Not applicable
- Mobile CARE-App to Promote Coping for Caregivers of Patients Receiving Stem Cell TransplantActive, not recruitingNCT05709912Not applicable
- Hospital at Home at EOL in Heme MalignanciesCompletedNCT04690205Not applicable
- CAR T-CELL Therapy Educational Video TrialStatus unknownNCT04280133Not applicable
- Non Invasive Optical Imaging of WBC CountCompletedNCT02512666Not applicable
- Evaluation of PET/MRI in Children with CancerCompletedNCT01839747Not applicable
- Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic MalignanciesTerminatedNCT00113828Phase 2
- Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic MalignanciesTerminatedNCT00113646Phase 2